Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1335

1.

Alendronate, a double-edged sword acting in the mevalonate pathway.

Tricarico PM, Girardelli M, Kleiner G, Knowles A, Valencic E, Crovella S, Marcuzzi A.

Mol Med Rep. 2015 Jun 18. doi: 10.3892/mmr.2015.3957. [Epub ahead of print]

PMID:
26096667
2.

Bisphosphonates and glucocorticoid-induced osteoporosis: cons.

Lems WF, Saag K.

Endocrine. 2015 Jun 4. [Epub ahead of print]

PMID:
26041376
4.

Trends in Media Reports, Oral Bisphosphonate Prescriptions and Hip Fractures 1996-2012: An Ecological Analysis.

Jha S, Wang Z, Laucis N, Bhattacharyya T.

J Bone Miner Res. 2015 May 27. doi: 10.1002/jbmr.2565. [Epub ahead of print]

PMID:
26018247
5.

Comparison of Bone Mineral Density in Lumbar Spine and Fracture Rate among Eight Drugs in Treatments of Osteoporosis in Men: A Network Meta-Analysis.

Chen LX, Zhou ZR, Li YL, Ning GZ, Zhang TS, Zhang D, Feng SQ.

PLoS One. 2015 May 26;10(5):e0128032. doi: 10.1371/journal.pone.0128032. eCollection 2015.

6.

Management of glucocorticoid-induced osteoporosis: clinical data in relation to disease demographics, bone mineral density and fracture risk.

Kenanidis E, Potoupnis ME, Kakoulidis P, Leonidou A, Sakellariou GT, Sayegh FE, Tsiridis E.

Expert Opin Drug Saf. 2015 Jul;14(7):1035-53. doi: 10.1517/14740338.2015.1040387. Epub 2015 May 8.

PMID:
25952267
7.
8.

Alendronate sodium/vitamin D<sub>3</sub> combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension.

Zhang ZL, Liao EY, Xia WB, Lin H, Cheng Q, Wang L, Hao YQ, Chen DC, Tang H, De Peng Y, You L, He L, Hu ZH, Song CL, Wei F, Wang J, Zhang L, Santora AC.

Osteoporos Int. 2015 May 1. [Epub ahead of print]

PMID:
25929192
9.

Bridging the osteoporosis treatment gap: performance and cost-effectiveness of a fracture liaison service.

Yates CJ, Chauchard MA, Liew D, Bucknill A, Wark JD.

J Clin Densitom. 2015 Apr;18(2):150-6. doi: 10.1016/j.jocd.2015.01.003. Epub 2015 Mar 18.

PMID:
25797867
10.

Osteoporosis prevalence and characteristics of treated and untreated nursing home residents with osteoporosis.

Zarowitz BJ, Cheng LI, Allen C, O'Shea T, Stolshek B.

J Am Med Dir Assoc. 2015 Apr;16(4):341-8. doi: 10.1016/j.jamda.2015.01.073. Epub 2015 Feb 25.

PMID:
25726417
11.

Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain.

DarbĂ  J, Kaskens L, Sorio Vilela F, Lothgren M.

Clinicoecon Outcomes Res. 2015 Feb 9;7:105-17. doi: 10.2147/CEOR.S78349. eCollection 2015.

12.

The Effect of Osteoporosis Treatments on Fatigue Properties of Cortical Bone Tissue.

Brock GR, Chen JT, Ingraffea AR, MacLeay J, Pluhar GE, Boskey AL, van der Meulen MC.

Bone Rep. 2015 Jun 1;2:8-13.

PMID:
25642445
13.

Bisphosphonate treatment of type I diabetic mice prevents early bone loss but accentuates suppression of bone formation.

Coe LM, Tekalur SA, Shu Y, Baumann MJ, McCabe LR.

J Cell Physiol. 2015 Aug;230(8):1944-53. doi: 10.1002/jcp.24929.

PMID:
25641511
14.

Mapping Bone Changes at the Proximal Femoral Cortex of Postmenopausal Women in Response to Alendronate and Teriparatide Alone, Combined or Sequentially.

Whitmarsh T, Treece GM, Gee AH, Poole KE.

J Bone Miner Res. 2015 Jul;30(7):1309-18. doi: 10.1002/jbmr.2454.

PMID:
25639838
15.

Femoral fracture and temporomandibular joint destruction following the use of bisphosphonates.

Skoglund K, Hjortdal O.

Tidsskr Nor Laegeforen. 2015 Jan 27;135(2):116-7. doi: 10.4045/tidsskr.14.1108. eCollection 2015 Jan 27. English, Norwegian. No abstract available.

16.

Evaluation of the effects of LLLT on biomechanical properties of tibial diaphysis in two rat models of experimental osteoporosis by a three point bending test.

Fridoni M, Masteri Farahani R, Nejati H, Salimi M, Gharavi SM, Bayat M, Amini A, Torkman G, Bayat S.

Lasers Med Sci. 2015 Apr;30(3):1117-25. doi: 10.1007/s10103-014-1706-1. Epub 2015 Jan 24.

PMID:
25616711
17.

Alendronate rescued osteoporotic phenotype in a model of glucocorticoid-induced osteoporosis in adult zebrafish scale.

Pasqualetti S, Congiu T, Banfi G, Mariotti M.

Int J Exp Pathol. 2015 Feb;96(1):11-20. doi: 10.1111/iep.12106. Epub 2015 Jan 21.

PMID:
25603732
18.
19.

Long-term efficacy, safety, and patient acceptability of ibandronate in the treatment of postmenopausal osteoporosis.

Inderjeeth CA, Glendenning P, Ratnagobal S, Inderjeeth DC, Ondhia C.

Int J Womens Health. 2014 Dec 17;7:7-17. doi: 10.2147/IJWH.S73944. eCollection 2015. Review.

20.

Treatment of primary osteoporosis in men.

Giusti A, Bianchi G.

Clin Interv Aging. 2014 Dec 30;10:105-15. doi: 10.2147/CIA.S44057. eCollection 2015.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk